Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Study of Adalimumab on Quality of Life, Health Care Utilization, and Costs in Ulcerative Colitis
2011-002411-29Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in autoimmune colitis, sponsored by AbbVie Inc. Primary endpoint: Change in SIBDQ at Week 26 from Baseline. Started Oct 2011; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2011-002411-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002411-29.